Methods of using ehmt2 inhibitors in immunotherapies
OwnerKat COSMOPOULOS, Elayne Penebreinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.
Claims34
A method of preventing or treating a disease or disorder associated with overexpression of EHMT2, comprising administering to a subject in need thereof a first agent in a therapeutically effective amount, wherein the first agent comprises an EHMT2 inhibitor.
(canceled)
A method of preventing or treating an immune-mediated disease, comprising administering to a subject in need thereof a first agent in a therapeutically effective amount, wherein the first agent comprises an EHMT2 inhibitor.
6-58. (canceled)
60-65. (canceled)
68-75. (canceled)
77-81. (canceled)
83-101. (canceled)
103-104. (canceled)
(canceled)
(canceled)
111-122. (canceled)
125-178. (canceled)
180-203. (canceled)
206-230. (canceled)
232-269. (canceled)
Dependencies are inferred from the claim text.